U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor-Expressing Metastatic Colorectal Carcinoma With Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-07-1354
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Oxaliplatin Plus Irinotecan Compared With Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2008English

Reply: Oxaliplatin- Or Irinotecan-Based Chemotherapy for Metastatic Colorectal Cancer in the Elderly

British Journal of Cancer
Cancer ResearchOncology
2004English

U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2016English

Adjuvant Oxaliplatin- Or Irinotecan-Containing Chemotherapy Improves Overall Survival Following Resection of Metachronous Colorectal Liver Metastases

International Journal of Colorectal Disease
Gastroenterology
2010English

Metastatic Colorectal Carcinoma: Response to Panitumumab

Journal of the Bahrain Medical Society
2018English

Capecitabine and Irinotecan as First- Line Chemotherapy for Patients With Metastatic Colorectal Cancer

Journal of IMAB - Annual Proceeding (Scientific Papers)
Dentistry
2011English

Cetuximab and Platinum-Based Chemoradio- Or Chemotherapy of Patients With Epidermal Growth Factor Receptor Expressing Adenoid Cystic Carcinoma: A Phase II Trial

British Journal of Cancer
Cancer ResearchOncology
2013English

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients With Intermediate and High-Risk Myelofibrosis

Clinical Cancer Research
Cancer ResearchOncology
2012English

Targeted Approach to Metastatic Colorectal Cancer: What Comes Beyond Epidermal Growth Factor Receptor Antibodies and Bevacizumab?

Therapeutic Advances in Medical Oncology
Oncology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy